DIPHARMA FRANCIS

Dipharma Group is a global CDMO and a leading manufacturer of APIs and advanced Intermediates for generic and contract manufacturing markets, offering about 40 APIs with DMFs lodged worldwide. Its fully equipped R&D Centres, located in the U.S.A. and Italy, develop innovative chemical processes and crystalline forms.
Since 1970, Dipharma has succeeded in achieving a positive unbroken record of major Regulatory Agency inspections, including the Japanese PMDA, and its 4 cGMP manufacturing sites are equipped to supply quantities from laboratory to industrial scale, covering the entire lifecycle of a drug substance.
Core technologies: High-pressure hydrogenation, Nitration, Nitroesterification, Azide chemistry, Borane reductions, Cross-coupling reactions, Curtius reaction, Dissolving metal reduction, Enzymatic chemistry, Epichlorohydrin chemistry, Hoffman reaction, Hydrogen peroxide oxidations, Carbohydrate chemistry, Enantioselective reactions, Use of nitroalkanes (Henry reaction).
Experience you can trust